OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a research report sent to investors on Wednesday morning. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Stock Performance

OPGN opened at $0.41 on Wednesday. OpGen has a fifty-two week low of $0.17 and a fifty-two week high of $3.84. The firm has a 50-day moving average of $0.57 and a 200 day moving average of $0.51. The firm has a market cap of $5.16 million, a P/E ratio of -0.06 and a beta of -0.71.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.